Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

C Hagen, C Hagen, M Andersen - European Journal of …, 2009 - academic.oup.com
Objective Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …
被引用次数：138 相关文章
[PDF] archive.org

[PDF][PDF] Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

C Hagen, HD Schroeder, S Hansen… - European Journal of …, 2009 - scholar.archive.org
Objective: Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

[引用][C] Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

C HAGEN, HD SCHROEDER… - European journal of …, 2009 - pascal-francis.inist.fr
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas
resistant to conventional therapy CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

C Hagen, HD Schrøder… - European Journal …, 2009 - portal.findresearcher.sdu.dk
OBJECTIVE: Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is
an alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

C Hagen, HD Schroeder… - European journal of …, 2009 - pubmed.ncbi.nlm.nih.gov
Objective Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

C Hagen, HD Schroeder, S Hansen… - European Journal of …, 2009 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective</jats: title>< jats: p> Aggressive pituitary tumours may
be difficult to treat. Temozolomide (TMZ) is an alkylating cytostaticum. In a small number of …
[PDF] researchgate.net

[PDF][PDF] Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

European Journal of Endocrinology, 2009 - researchgate.net
Objective: Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.

C Hagen, HD Schroeder, S Hansen… - European Journal of …, 2009 - search.ebscohost.com
Objective: Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.

C Hagen, HD Schroeder, S Hansen… - European Journal of …, 2009 - europepmc.org
Objective Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

[引用][C] Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

C HAGEN, HD SCHROEDER, S HANSEN… - European journal of …, 2009 - BioScientifica